Nature Communications

Efficacy and safety of low-dose interleukin 2 for Behçet’s syndrome: a randomized, placebo-controlled, double-blind, phase 2 clinical trial

2026-01-07

Full text

DOI https://doi.org/10.1038/s41467-025-68100-w